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Abstract
Background: KL-6 is a high-molecular-weight glycoprotein classified as a human MUC1 mucin. It was hypothesized
that KL-6 could be detectable in the circulating blood and especially in airway secretions in lung diseases
associated with mucus production such as chronic obstructive pulmonary disease (COPD). Additional aims of this
study were to investigate whether the levels of KL-6 in plasma and sputum are related to ageing and smoking
history.
Methods: The concentrations of KL-6 in plasma and induced sputum supernatants from young and/or middle
aged/elderly non-smokers, smokers and patients with COPD were assayed by ELISA (n = 201). The subjects were
classified into five groups according to age, smoking status and presence of COPD. In addition, KL-6 expression in
control and diseased lung i.e. samples from patients with COPD (n = 28), were analyzed by immunohistochemistry
and digital image analysis.
Results: The plasma levels of KL-6 increased with age both in non-smokers and smokers. Among middle aged/
elderly subjects, plasma KL-6 levels in all smokers regardless of COPD were significantly higher than in non-
smokers, whereas sputum levels of KL-6 were significantly higher in COPD compared not only to non-smokers but
also to smokers. KL-6 was more prominently expressed in the bronchiolar/alveolar epithelium in COPD than in the
control lungs. Plasma and sputum KL-6 levels correlated inversely with obstruction and positively with smoking
history and ageing. The linear multiple regression analysis confirmed that age and cigarette smoking had
independent effects on plasma KL-6.
Conclusions: KL-6 increases with ageing and chronic smoking history, but prospective studies will be needed to
elucidate the significance of KL-6 in chronic airway diseases.
Background
Smokers are particularly vulnerable to suffer from
chronic obstructive pulmonary disease (COPD) and sev-
eral co-morbidities [1,2]. The risk of COPD increases
with age and smoking history [3-5], but very little is
known about the cumulative effects of ageing and long-
term smoking on human lungs.
Several markers of oxidant burden and inflammation
are elevated in smokers who have not developed obstruc-
tion/COPD [6-10]. However, these markers are not speci-
fic for smoking or COPD [10]. The epithelial lining fluid
and mucins provide the first line of defense in the lung
[11-14]. KL-6 is high-molecular-weight mucus glycopro-
tein also classified as a human MUC1 mucin [15-17].
Purified KL-6 can be detected by anti-MUC1 core pro-
tein antibody [16,17], and these studies have concluded
that KL-6 is one subtype of the MUC1 glycoprotein.
Serum KL-6 has been reported to represent a sensitive
biomarker for interstitial lung diseases (ILDs) [18-20],
but presumably KL-6 can be detectable also in airway
secretions especially in disorders associated with mucus
production such as COPD.
To test this hypothesis, the levels of KL-6 were
assayed from plasma and induced sputum samples from
European i.e. Finnish young and middle aged/elderly
non-smokers and smokers and patients with COPD, and
the distribution/expression of KL-6 was investigated by
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immunohistochemistry and image analysis in the control
and diseased lung.
Methods
Subjects
Plasma and induced sputum samples from middle aged/
elderly subjects were collected from subjects who had
been contacted from Lapland Central Hospital [5].
Young smokers and non-smokers were military draftees
from Northern Finland [21]. Details of these cohorts
have been described [5,21]. Based on self-reported
detailed questionnaire, all the subjects considered them-
selves as healthy, they had no other environmental expo-
sures (second hand smoke, pollutants or asbestos fibers)
[5]. The diagnosis of COPD was defined according to the
Global Strategy for the diagnosis, management and pre-
vention of COPD (GOLD) criteria; FEV1 <80% of pre-
dicted, FEV1/FVC <70% and bronchodilatation effect
<12% [2,22,23]. Current young smokers and non-smokers
had no airway obstruction (post-bronchodilator FEV1/
FVC > 70%) and no significant reversibility. Exclusion
criteria included allergies, asthma, a history of respiratory
disease, or a respiratory infection less than 8 weeks
before entering the study. Diagnosis of COPD in the
plasma and sputum studies was confirmed during the
study. None of these subjects had any previously pre-
scribed medication for COPD or other diseases; and all
the smokers were current smokers.
Tissue samples were collected from patients treated in
Helsinki University Central Hospital. All control tissue
samples and COPD cases were obtained from the opera-
tions of hamartomas, local lung tumors or lung trans-
plantations. Five mg oral prednisolone and/or inhaled
corticosteroids had been included in the therapy of all
patients with Stage III-IV (severe-very severe) COPD,
whereas none of the other subjects were receiving corti-
costeroid therapy. The Ethics Committees of the Hel-
sinki University Central Hospital and Lapland Central
Hospital approved the study and all patients signed writ-
ten information to use the samples.
Plasma samples
Peripheral whole venous blood was collected into EDTA
tubes. Plasma was prepared by centrifugation for 10-15
min at 1,500 × g and stored at - 80 C until analysed.
Induced sputum
Sputum was induced by inhalation of hypertonic saline
and treated with dithioerythritol (DTE, Sigma, Germany)
as recommended by the European Respiratory Society
Task Force [6,24]. For the differential cell count the sam-
ple was smeared over glass slides, fixed and stained with
Papanicolau stain and examined in a light microscope at
1000× magnification [25,26]. The supernatant was frozen
at -80°C prior to the analyses.
Measurement of KL-6 levels in plasma and induced
sputum
KL-6 levels in plasma and induced sputum were measured
by sandwich-type enzyme-linked immunosorbent assay
(ELISA) using an Eitest KL-6 ELISA kit (a kind gift from
Sanko Junyaku, Tokyo, Japan) according to the manufac-
turer’s protocol as described [27]. In brief, the range of
KL-6 detection is 201-4020 U/mL and the range of the
standard antigen 1-20 U/mL when this kit is used by the
dilution ratio 201-fold. For samples containing antigen
concentrations of less than 201 U/ml, concentration
can be obtained in the range of 3-600 U/ml by changing
the dilution from 201 to 3-fold. Then, the detection
limit of KL-6 in this study was 3 U/ml (ranging from
3-4020 U/ml).
Immunohistochemistry and image analysis
Four mm thick paraffin-embedded tissue sections were
deparaffinized, and antigens retrieved by heating the
sections in citrate buffer (pH 6.0). NovoLink polymer
detection system (RE7150-CE, Novocastra Laboratories
ltd, Newcastle Upon Tyne, UK) was used for immu-
nostaining according to the manufacturer’s instruc-
tions. Monoclonal antibody to KL-6 (a kind gift from
Sanko Junyaku, Tokyo, Japan) was used at 10 μg/ml.
To determine the specificity of the staining, negative
control sections were treated with mouse isotype con-
trol (Zymed Laboratories, San Francisco, CA, USA) or
PBS. Two or three representative images from the lung
parenchyma of each stained section were taken with
an Olympus U-CMAD3 camera (Olympus Corpora-
tion, Japan) and QuickPHOTO CAMERA 2.1 software
(Promicra, Praque, Czech Republic). Quantitative
image analysis of the stained tissue sections was con-
ducted as described [28]. The areas of positively vs
negatively stained bronchiolar/alveolar epithelium,
interstitium, and macrophages were measured with
Image-Pro Plus 6.1. software (Media Cybernetics, UK).
Statistical analysis
Data are presented as the mean ± SEM. The data were
analyzed with a statistical software package (SPSS for
Windows, version 15.0; SPSS Inc; Chicago, IL) and P <
0.05 was considered to indicate a significant difference.
Data for individual variables from the various groups
were first analyzed by the Kruskal-Wallis test followed
by the Mann-Whitney U-test. Linear and multivariate
regression analysis was conducted to study the indepen-
dent effect of age, body mass index (BMI), smoking sta-
tus and COPD on KL-6.
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Results
Plasma levels of KL-6 increase with ageing being highest
in chronic smokers and patients with COPD
The clinical characteristics and lung function data (63
young subjects and 138 middle aged/elderly subjects) are
shown in Table 1. The age of the young subjects was in
the range 18-22 years and the middle aged/elderly subjects
35-79 years. Plasma levels of KL-6 in the five groups are
shown in Figure 1A. The plasma levels of KL-6 increased
with age both in non-smokers and smokers (p = 0.008 and
p < 0.001, respectively). In the young subjects, the mean
plasma levels of KL-6 did not differ between the non-smo-
kers and smokers (mean ± SEM, young non-smoker 172 ±
12 U/ml, young smoker 160 ± 19 U/ml). In the middle
aged/elderly subjects, the mean plasma level of KL-6 was
higher in both smokers and subjects with COPD when
compared to non-smokers (non-smoker 309 ± 35 U/ml,
smoker 478 ± 31 U/ml, COPD 589 ± 61 U/ml; p = 0.003
and p < 0.001, respectively). There were more women in
the middle aged/elderly group than in the young group.
Therefore, these 201 middle aged/elderly subjects were
divided into two subgroups by gender. Mean plasma level
of KL-6 was higher in the middle aged/elderly males with
COPD when compared to non-smokers in the group
(middle aged/elderly male non-smokers 292 ± 78 U/ml,
middle aged/elderly males with COPD 556 ± 64 U/ml;
p = 0.037) (Figure 1B).
Sputum levels of KL-6 increase in COPD
The levels of KL-6 were next investigated in the induced
sputum obtained from 15 middle aged/elderly non-smo-
kers, 20 smokers and 19 patients with COPD (Table 2).
In the middle aged/elderly subjects, female gender and
younger age were more predominant in non-smokers
than in the COPD patients. The difference in the
induced sputum levels of KL-6 between the non-smoker,
smoker and COPD groups was significant (p = 0.008)
(Figure 2A). The mean induced sputum level of KL-6
was higher in patients with COPD than in the middle
aged/elderly smokers without COPD; 203 ± 41 U/ml vs
96 ± 22 U/ml, p = 0.002), the corresponding value
in the middle aged/elderly non-smokers being 68 ±
20 U/ml, p = 0.033). Mean induced sputum level of KL-
6 was higher in the middle aged/elderly males with
COPD when compared to the non-smokers in the
group (middle aged/elderly male non-smokers 54 ±
13 U/ml, middle aged/elderly males with COPD 232 ±
64 U/ml; p = 0.021) (Figure 2B).
KL-6 is prominently expressed in the bronchiolar/alveolar
epithelium in COPD lungs
Next, the distribution of KL-6 in the lung tissue was
investigated in 7 non-smoking controls, 7 smokers and
14 patients with COPD (Table 3). In agreement with
earlier published data [15,18], KL-6 could be detected in
the alveolar type II cells and macrophages in all lung
specimens (Figure 3A). In addition, KL-6 was expressed
in the bronchiolar/alveolar epithelial cells and intersti-
tium in COPD. Since KL-6 has not been evaluated in
COPD lungs earlier, the distribution and quantitation
was conducted by using digital image analysis. There
was significant difference in the KL-6 positive areas
(sum of the bronchiolar/alveolar epithelium, intersti-
tium, and macrophages; Epi+Int+Mac, respectively)
between the three groups (p = 0.005) (Figure 3B).
Patients with COPD displayed higher KL-6 positive area
in general (Epi+Int+Mac) compared to the findings in
the lungs in non-smokers or smokers (p < 0.001 and
p = 0.010, respectively). KL-6 was also expressed in
macrophages, which are phagocytic cells. When macro-
phages were excluded from these calculations (sum of
the bronchiolar/alveolar epithelium and interstitium; Epi
Table 1 Characteristics of the subjects in the plasma analyses
Variable Young Middle aged/elderly
Non-smokers Smokers Non-smokers Smokers COPD
Subjects, n 28 35 34 64 40
Age, yr 20 ± 0.2 20 ± 0.1 56 ± 1.7 52 ± 1.0 61 ± 1.4**
Sex, M/F 26/2 34/1 9/25 40/24** 31/9***
Pack years, yr 0 5.0 ± 0.43††† 0 30.5 ± 1.78*** 39.6 ± 2.39***
Post bronchodilator
FVC (l) 5.5 ± 0.17 5.4 ± 0.14 3.6 ± 0.11 4.0 ± 0.11 3.8 ± 0.15
FEV1 (l) 4.8 ± 0.14 4.7 ± 0.11 3.0 ± 0.09 3.3 ± 0.09 2.3 ± 0.12***
FEV1 (% predicted) 98 ± 1.2 100 ± 1.6 106 ± 2.3 95 ± 1.5*** 71 ± 2.7***
FEV1/FVC 88 ± 1.0 88 ± 0.8 84 ± 1.0 83 ± 0.6 61 ± 1.5***
Data are shown as mean ± SEM
COPD, chronic obstructive pulmonary disease; FVC, Forced vital capacity; FEV1, Forced expiratory volume in one second
†p < 0.05; ††p < 0.01; †††p < 0.001 (vs young non-smokers, Mann-Whitney U test or Chi-square test)
*p < 0.05; **p < 0.01; ***p < 0.001 (vs middle aged/elderly non-smokers, Mann-Whitney U test or Chi-square test)
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+Int), the difference among the three groups remained
significant (p = 0.002) (Figure 3C). When the KL-6 posi-
tive area in bronchiolar/alveolar epithelium was evalu-
ated but excluding macrophages and interstitium (Epi),
the difference among the three groups was still signifi-
cant (p < 0.001). Smokers, as well as the patients with
COPD displayed higher KL-6 positive bronchiolar/alveo-
lar epithelium (sum of the bronchiolar/alveolar epithe-
lium; Epi) than non-smoker’s lung (p = 0.006 and p <
0.001, respectively), and the epithelial positivity was
more prominent in the COPD than in the smoker’s lung
(Figure 3D).
KL-6 levels correlate inversely with obstruction and
positively with smoking history
The correlations between the KL-6 levels and several
clinical parameters including age, smoking status and
lung function values are shown in Tables 4 and 5.
Table 2 Characteristics of the subjects in the induced sputum analyses
Variable Middle aged/elderly
Non-smokers Smokers COPD
Subjects, n 15 20 19
Age, yr 52 ± 1.9 52 ± 1.5 61 ± 1.9***
Sex, M/F 5/10 13/7 17/2**
Pack years, yr 0 29 ± 1.9*** 45 ± 3.8***
Post-bronchodilator
FVC, l 3.9 ± 0.21 4.2 ± 0.19 3.6 ± 0.15
FEV1, l 3.3 ± 0.15 3.5 ± 0.13 2.1 ± 0.13***
FEV1, % predicted 107 ± 3.9 100 ± 1.7 64 ± 3.2***
FEV1/FVC 86 ± 1.4 83 ± 1.0 59 ± 2.7***
Data are shown as mean ± SEM
COPD, chronic obstructive pulmonary disease; FVC, Forced vital capacity; FEV1, Forced expiratory volume in one second
*p < 0.05; **p < 0.01; ***p < 0.001 (vs middle aged/elderly non-smokers, Mann-Whitney U test or Chi-square test)
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Figure 1 KL-6 levels in plasma. KL-6 levels in plasma obtained from young subjects (non-smokers; NS and smokers; S) and middle aged/elderly
subjects (non-smokers, smokers and COPD) in (A) both males and females, and in (B) males only. The box represents the 25th to 75th percentiles,
the solid lines within the boxes show the median values, the whiskers are the 10th and 90th percentiles, and the points represent outliers.
Horizontal bars indicate mean values. †p < 0.05; ††p < 0.01; †††p < 0.001 (young non-smokers vs young smokers, Mann-Whitney U test). *p <
0.05; **p < 0.01; ***p < 0.001 (middle aged/elderly non-smokers vs middle aged/elderly smokers or COPD, Mann-Whitney U test).
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A linear regression analysis confirmed that age (regres-
sion coefficient (B) = 8.178, standard error (SE) = 0.960,
p < 0.001), BMI (B = 12.879, SE = 5.285, p = 0.016),
Pack-year (B = 6.765, SE = 0.939, p < 0.001) and FEV1/
FVC (B = -8.507, SE = 1.684, p < 0.001) had significant
effects on the KL-6 levels in plasma (Table 4), and that
age (B = 4.747, SE = 2.360, p = 0.049), Pack-year (B =
2.921, SE = 0.942, p = 0.003) and FEV1/FVC (B =
-0.3034, SE = 1.415, p = 0.037) had significant effects on
the KL-6 levels in induced sputum (Table 5). In
addition, multivariate regression analyses demonstrated
that age (B = 6.383, SE = 1.262, p < 0.001) and pack-
year (B = 3.832, SE = 1.251, p = 0.002) had independent
significant effects on plasma KL-6 (Table 4).
Discussion
The present study supports the hypothesis that KL-6 is
associated with the pathogenesis of cigarette smoke
induced lung damage and COPD. Plasma levels of KL-6
were found to be elevated with age both in non-smokers
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Figure 2 KL-6 levels in induced sputum. KL-6 levels in induced sputum obtained from middle aged/elderly subjects (non-smokers; NS,
smokers; S and COPD) in (A) both males and females, and in (B) males only. The box represents the 25th to 75th percentiles, the solid lines
within the boxes show the median values, the whiskers are the 10th and 90th percentiles, and the points represent outliers. Horizontal bars
indicate mean values. *p < 0.05; **p < 0.01; ***p < 0.001 (middle aged/elderly non-smokers vs middle aged/elderly smokers or COPD, Mann-
Whitney U test).
Table 3 Characteristics of the controls and subjects with COPD in the immunohistochemical analyses of the lung
Non-smokers Smokers COPD
Subjects, n 7 7 14
Age, yr 65 ± 3.1 62 ± 2.6 60 ± 2.1
Sex, M/F 3/4 6/1 9/4
Pack years, yr - † 24 ± 5.7 37 ± 3.8
Post-bronchodilator
FVC, l 4.5 ± 0.56 3.7 ± 0.25 2.4 ± 0.31**
FEV1, l 3.5 ± 0.47 3.1 ± 0.19 1.2 ± 0.24**
FEV1, % predicted 106 ± 4.6 88 ± 3.5* 34 ± 6.1***
FEV1/FVC 79 ± 2.8 82 ± 2.3 45 ± 5.3**
Data are shown as mean ± SEM
COPD, chronic obstructive pulmonary disease; FVC, Forced vital capacity; FEV1, Forced expiratory volume in one second
† Two of the controls were never smokers and four of the controls had smoked for between 10-30 years but had stopped smoking at least 2 years before the
study.
*p < 0.05; **p < 0.01; ***p < 0.001 (vs non-smokers, Mann-Whitney U test or Chi-square test)
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and smokers. In addition, in middle aged/elderly sub-
jects, plasma levels of KL-6 in all smokers were higher
than in non-smokers. A multivariate regression analysis
demonstrated that KL-6 was clearly correlated with age
and pack-years. One important new finding was the
higher level of KL-6 in the sputum samples of COPD
patients compared not only to non-smokers but also to
those found in smokers. KL-6 was more prominently
expressed in the bronchiolar/alveolar epithelium in
COPD lungs than in non-smokers’ and smokers’ lung.
As far as we are aware, this is the first study on KL-6
Figure 3 KL-6 expression and localization in diseased lung. (A) KL-6 expression and localization in representative sections of lung specimens
from non-smoker, smoker, and patient with COPD. Positive KL-6 expression was seen mainly in type II pneumocytes as well as in macrophages
in the lungs of non-smokers, smokers, and patients with COPD. The bronchial/alveolar epithelium of patients with COPD displayed highly
positive areas of KL-6 staining in contrast to the situation in non-smokers and smokers. (B) Quantitative image analysis of KL-6 in the lung tissues
of 7 non-smokers, 7 smokers and 14 patients with COPD. Three representative areas consisting of the parenchymal portion of the lung tissue
were analyzed from all stained sections (sum of the bronchiolar/alveolar epithelium, interstitium and macrophages; Epi+Int+Mac). Quantitative
image analysis of the immunoreactivity for KL-6 was also conducted separately in the bronchial/alveolar epithelium and interstitium (sum of the
bronchiolar/alveolar epithelium and interstitium; Epi+Int; C) or the bronchial/alveolar epithelium (sum of the bronchiolar/alveolar epithelium; Epi;
D). Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (between all four groups, Kruskall-Wallis test). For patient
characteristics see Table 3.
Table 4 Linear and multivariate analysis of the
relationship between the plasma levels of KL-6 and
clinical parameters
Variable Regression
coefficient
Standard
error
P-value
Linear
Regression
Age 8.178 0.960 <0.001***
BMI 12.879 5.285 0.016*
Pack-year 6.765 0.939 <0.001***
FEV1/FVC -8.507 1.684 <0.001**
Multi
Regression
Age 6.383 1.262 <0.001***
BMI -3.464 4.999 0.489
Pack-year 3.832 1.251 0.002**
FEV1/FVC 1.008 2.054 0.624
BMI, body mass index; FEV1, Forced expiratory volume in one second; FVC,
Forced vital capacity
Table 5 Linear and multivariate analysis of relationship
between the induced sputum levels of KL-6 and clinical
parameters
Variable Regression
coefficient
Standard
error
P-value
Linear
Regression
Age 4.747 2.360 0.049*
BMI 5.971 5.427 0.276
Pack-year 2.921 0.942 0.003**
FEV1/FVC -3.034 1.415 0.037*
Multi
Regression
Age 1.506 2.713 0.581
Pack-year 2.566 1.409 0.075
FEV1/FVC -0.056 1.940 0.977
BMI, body mass index; FEV1, Forced expiratory volume in one second; FVC,
Forced vital capacity
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distribution/expression in human lung tissues and the
effects of ageing and long-term smoking on KL-6 levels
in plasma and induced sputum obtained from a non-
Asian population over a wide age range.
KL-6 is a high-molecular weight (>200 kd) mucus gly-
coprotein, which belongs to MUC1 protein [15-17].
Chronic productive cough is associated with mucus
hypersecretion and airway inflammation [29]. Mucins
provide significant protection against oxidants, and the
levels of these glycoproteins are increased by exposure
to oxidants [30]. KL-6/MUC1 expression is also elevated
by oxidative stress, and MUC1 in turn induces the
expression of several anti-oxidant enzymes, and attenu-
ates apoptotic response to oxidative stress [31]. It is
therefore surprising that KL-6 has not been earlier eval-
uated from the circulating blood or from airway secre-
tions of smokers and/or patients with COPD.
Another new finding from this study was that among
middle aged/elderly subjects, when compared to non-
smokers, the plasma KL-6 level was already elevated in
smokers regardless of COPD diagnosis. This difference
could not be seen in young smokers. This finding is in
agreement with earlier studies that have reported serum
levels of KL-6 correlating with age but not smoking his-
tory among healthy young/middle aged Caucasian sub-
jects [27,32]. An additional strength of this study is that
the subjects included in the plasma and sputum studies
had no history of exposures to other agents and no co-
morbidities and medications.
The circulating KL-6 levels were higher than those ear-
lier reported in Japanese control subjects [18,33]. KL-6
levels were studied from plasma, whereas Japanese values
have been published from serum. On the other hand, an
earlier study has demonstrated that serum and plasma
levels of KL-6 are very similar [34]. A recent study on the
functional A to G MUC1 gene polymorphism at nucleo-
tide position 568 (exon 2; rs4072037) and the variation of
serum levels of KL-6 in Caucasian subjects, showed that
the highest serum KL-6 levels can be detected in the GG
genotype, the lowest levels in AA genotype with inter-
mediate levels in the AG genotype [32]. According to the
HapMap data http://hapmap.ncbi.nlm.nih.gov/, the geno-
type frequency for AA, AG and GG genotype in Eur-
opean subjects (30.1%, 55.8% and 14.2%, respectively)
differs from Japanese subjects (69.8%, 25.6% and 4.7%,
respectively). Overall, the cut-off level for KL-6 in the
European is probably higher than in the Asian/Japanese
population but will require further investigations.
Mucins have an important role in the pathogenesis of
chronic airway disease [35]. In this study, the levels of
KL-6 in induced sputum were comparable with those in
circulating blood, indicating that an extremely large
volume of KL-6 exists in the ELF of the patients with
COPD. Furthermore, sputum levels of KL-6 were higher
in COPD compared not only to middle aged/elderly
non-smokers but also to smokers. Based on these new
findings, the level of KL-6 in induced sputum may be
more sensitive and more specific than KL-6 in the circu-
lating blood for the evaluation of COPD.
Sputum levels of KL-6 were elevated in patients with
COPD but not in “healthy” smokers or non-smokers.
Induced sputum reflects mainly large airway pathology.
KL-6 was mainly localized in bronchial/alveolar epithe-
lium and alveolar macrophages both in the healthy and
diseased lung, and significantly elevated in specific cell
types in smokers and/or COPD even though the num-
ber of the cases was relatively low. Since KL-6 is a high
molecular weight glycoprotein, both alveolar-capillary
destruction and enhancement of alveolar-capillary per-
meability are probably needed for the elevation of circu-
lating KL-6 related molecules [36]. Taken together, it
can be concluded that sputum KL-6 could be good bio-
marker for the injury in distal airways, but it does not
reflect smoking induced alterations in the airways of
“healthy” lung.
There were some limitations. First, the sample size was
relatively small. Secondly, there was individual variability
between the subjects, especially in the sputum levels of
KL-6, which is in line with previous studies showing that
the repeatability of sputum in longitudinal studies is, at
best, only satisfactory [37]. Thirdly, we did not perform
high resolution computed tomography (HRCT) scan,
which could give more information about the COPD
sub-phenotypes. Patients with combined pulmonary
fibrosis and emphysema (CPFE) are not very uncommon,
and these particular patients have high levels of circulat-
ing KL-6 [38]. In spite of these concerns, the results are
straightforward and significant. Considering ethnic differ-
ences in the prevalence of a-1-antitrypsin (AAT) defi-
ciency and the MUC polymorphism (rs4072037) [39], the
results need to be cautiously interpreted for Asian/Japa-
nese patients. This was also a cross-sectional study, and
therefore the validation and definition of the specificity
of these proteins in various chronic airway diseases will
also require further investigations. Prospective follow-up
is currently ongoing in two Finnish cohorts, which con-
tain smokers and patients with COPD [5,40].
Conclusions
In conclusion, ageing alone and/or long-term smoking
appears to lead to an increase in plasma and sputum
KL-6, but prospective studies will be needed to elucidate
the significance of these findings in the development
and progression of COPD.
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